Olatoyosi Odenike to Myeloid-Lymphoid Leukemia Protein
This is a "connection" page, showing publications Olatoyosi Odenike has written about Myeloid-Lymphoid Leukemia Protein.
Connection Strength
0.314
-
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol. 2025 Aug 10; 43(23):2606-2615.
Score: 0.228
-
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
Score: 0.085